Urology Update: For Primary Care and Advanced Practice Providers Webcast (2017)

The purpose of this program is to provide primary healthcare professionals, advanced practice providers and allied healthcare professionals with practical knowledge that will allow them to respond effectively to the needs of patients with urologic diseases.  
 
Topics to be addressed include oncology and voiding dysfunction with a focus on the review of AUA Guidelines.  

Target Audience

  • Internists
  • Family practitioners
  • Nurse practitioners
  • Physician assistants
  • Allied healthcare professionals
  • Other primary healthcare professionals

Learning Objectives

After attending this course, participants will be able to:

  1. Effectively utilize the AUA Guidelines.

Prostate Cancer               

  1. Discuss the epidemiology and genetic factors.                                             
  2. Describe the PSA controversy and AUA guideline recommendations.         
  3. Identify the diagnostic methods of staging and grading of prostate cancer.           
  4. Review the treatment options for localized and advanced cancer. 

Bladder Cancer                                                                                                                

  1. Discuss the epidemiology and risk factors.
  2. Identify the diagnostic methods of staging and grading of bladder cancer.
  3. Describe the use of Intravesical therapy for non-invasive bladder cancer.
  4. Compare treatment options for muscle invasive bladder cancer – surgical, radiotherapy, and chemotherapy.        

Renal Cancer                                                                                                                                

  1. Discuss the epidemiology and genetic risk factors.
  2. Review the treatment options for renal cell cancer and transitional cell kidney cancer.
  3. Discuss new and exciting chemotherapeutic treatment options for advanced renal cell carcinoma.

Stress Urinary Incontinence         

  1. Explain the etiology of stress incontinence in women and associated comorbidities.
  2. Outline appropriate evaluation for stress incontinence.
  3. Review current treatment options available for stress incontinence and when to refer.

Overactive Bladder                                                                                                          

  1. Outline a stepwise evaluation for the patient with overactive bladder.
  2. Describe management options for OAB including pharmacotherapy, Botox and Neuromodulation according to AUA/SUFU guidelines.
  3. Determine when it is appropriate to refer to a specialist.

Nocturia

  1. Identify common causes and comorbidities associated with nocturia.
  2. Describe the baseline evaluation and appropriate testing for initial work up of nocturia.
  3. Outline various treatment options for nocturia including when to initiate referral to an appropriate specialist.

Bladder Pain Syndrome/Interstitial Cystitis – Females

  1. Discuss the diagnosis and treatment of interstitial cystitis.
  2. Identify the associated organ systems involved with chronic pelvic pain. 
Course summary
Available credit: 
  • 4.50 AMA PRA Category 1 Credit™
  • 4.50 Non-Physician Participation
  • 4.50 AAFP Prescribed
Course opens: 
06/01/2017
Course expires: 
06/01/2018
Rating: 
0

Faculty Disclosures
 
Course Director:

  • Howard Neil Winfield, MD: Nothing to disclose

 
Course Faculty:

  • Matthew R. Thom, MD, FACS: Nothing to disclose
  • Michael A. O’Donnell, MD: Viventia: Consultant or Advisor; Photocure: Scientific Study or Trial; Telesta: Consultant or Advisor; Roche/Genentech:   Scientific Study or Trial; Medical Enterprises: Consultant or Advisor, Scientific Study or Trial; Theralase: Consultant or Advisor, Investment Interest; Spectrum Pharmaceuticals: Consultant or Advisor; Fidia Pharmaceuticals: Consultant or Advisor; Abbott Molecular: Scientific Study or Trial
  • David S. Wang, MD: Nothing to disclose
  • Sandip Prasan Vasavada, MD: NDI Medical LLC: Investment Interest; allergan: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Medtronic: Meeting Participant or Lecturer; axonics: Consultant or Advisor                                 
  • Jason Worcester, MD: Nothing to disclose 

Planner Disclosures

Education Council:

  • Timothy Charles Brand, M.D.: Nothing to disclose
  • Anthony A. Caldamone MD: Nothing to disclose
  • Peter Robert Carroll, MD, MPH: NIH: Scientific Study or Trial; Department of Defense: Scientific Study or Trial; AUA Update: Leadership Position; Genomic Health: Scientific Study or Trial
  • Sam S. Chang, MD: astellas: Consultant or Advisor; NIH: Scientific Study or Trial; GLG: Consultant or Advisor; Janssen: Consultant or Advisor; tolmar: Consultant or Advisor
  • Matthew S. Christman MD: Nothing to disclose
  • Jody Donaldson m (AUA Staff): Nothing to disclose
  • Shelby Englert (AUA Staff): Nothing to disclose
  • Matthew Thomas Gettman, MD: Nothing to disclose
  • Inderbir Singh Gill ,MD, M.Ch.: Nothing to disclose
  • Howard B. Goldman, MD: allergan: Consultant or Advisor; astellas: Consultant or Advisor; Medtronic: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Cook: Scientific Study or Trial; Nuvectra: Consultant or Advisor; Axonics: Consultant or Advisor
  • William C. Huang, MD: Photocure: Scientific Study or Trial; Karl Storz: Scientific Study or Trial
  • William C. Hulbert Jr. MD: Nothing to disclose
  • Brant Inman, M.D., MS, FRCSC: Dendreon: Scientific Study or Trial; Abbott Laboratories: Scientific Study or Trial; Genentech Inc: Scientific Study or Trial; Combat Medical: Consultant or Advisor; FKD Therapies: Scientific Study or Trial; AstraZeneca: Consultant or Advisor; Taris Biomedical: Consultant or Advisor
  • Mark L. Jordan MD,FACS: Nothing to disclose
  • Hari K. Koul, MSC,PHD: Novartis Pharmaceuticals: Consultant or Advisor; Urologic Research; Leadership Position; PLOS one: Leadership Position; OMICS group: Leadership Position; Open Access Publishing: Leadership Position, Health Publishing
  • Martin A. Koyle MD: Nothing to disclose
  • John Stephen Lam MD: Nothing to disclose
  • Yair Lotan ,MD: abbott: Scientific Study or Trial; Cepheid: Consultant or Advisor, Scientific Study or Trial; Pacific Edge: Scientific Study or Trial; FKD: Scientific Study or Trial; MDxHealth: Consultant or Advisor, Scientific Study or Trial; biocancell: Scientific Study or Trial: Genomic Health: Scientific Study or Trial; GenomeDx Biosciences Inc: Scientific Study or Trial; photocure: Consultant or Advisor, Scientific Study or Trial
  • Nicole Lara Miller ,MD: Boston Scientific Corporation: Consultant or Advisor, Meeting Participant or Lecturer; Practical Reviews In Urology: Health Publishing
  • Manoj Monga, MD, FACS: Fortec: Other; endourology society: Leadership Position
  • Victor William Nitti MD: Astellas: Health Publishing, Scientific Study or Trial; Allergan: Health Publishing, Scientific Study or Trial; Serenity Pharmeuticals: Investment Interest; Cook Myosite: Scientific Study or Trial; Medtronic: Scientific Study or Trial
  • Christopher Porter, MD: Nothing to disclose
  • Gail S. Prins PhD: Nothing to disclose
  • Ganesh V. Raj MD, PhD: Ptares: Owner, Product Development; C-diagnostics corp: Consultant or Advisor, Investment Interest; amgen: Meeting Participant or Lecturer; Johnson and Johnson: Consultant or Advisor, Owner, Product Development; Astellas: Meeting Participant or Lecturer; ASTELLAS: Consultant or Advisor, Meeting Participant or Lecturer; Janssen: Owner, Product Development; BAYER: Consultant or Advisor, Meeting Participant or Lecturer; SANOFI: Consultant or Advisor, Meeting Participant or Lecturer; Gaudium: Leadership Position, Investment Interest, Owner, Product Development; Medivation: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial
  • Jay D. Raman, MD: American Kidney Stone Management: Investment Interest; Pacific Edge Biotechnology: Scientific Study or Trial
  • Lee Richstone, MD: Nothing to disclose
  • Heather Schultz, NP: SUNA: Meeting Participant or Lecturer
  • Karl-Dietrich Sievert ,MD, PhD: AMS: Meeting Participant or Lecturer; Medtronics: Meeting Participant or Lecturer, Scientific Study or Trial; Allergen: Consultant or Advisor, Meeting Participant or Lecturer, Scientific Study or Trial; Neotract: Meeting Participant or Lecturer; Stimguard: Meeting Participant or Lecturer, Scientific Study or Trial
  • Joseph A. Smith Jr.,MD: Nothing to disclose
  • Ryan Patrick Terlecki, MD, FACS: American Medical Systems: Consultant or Advisor, Other; Allergan: Scientific Study or Trial
  • Edouard John Trabulsi, MD: Nothing to disclose

Advanced Practice Providers Education Committee:

  • Timothy Charles Brand, M.D.: Nothing to disclose
  • Anne E. Calvaresi NP,CRNP: Nothing to disclose
  • Jody Donaldson: Nothing to disclose
  • Todd James Doran, ED.D, PA-C, DFAAPA: Physician Assistant Education Association: Other
  • Shelby Englert: Nothing to disclose
  • James R. Kovarik III, PA-C: Nothing to disclose
  • Thomas Patrick McBride: Nothing to disclose
  • Kenneth Mitchell, MPAS, PA-C: Nothing to disclose
  • Karen A. Poe NP: Nothing to disclose
  • Jody A. Purifoy, DNP, APRN, CNP: Nothing to disclose
  • Ashleigh Renitsky, PA-C: Nothing to disclose
  • Thomas Alan Rozanski ,MD: Nothing to disclose
  • Rochell L. Sasse ,MSN, RN, ACNP: Metronic: Consultant or Advisor
  • Heather Schultz, NP: SUNA: Meeting Participant or Lecturer
  • Daniel Thomas Vetrosky, PA-C: Nothing to disclose
  • Gwendolyn Brooke Zilinskas ,PA-C: Kimberly-Clark Corporation: Meeting Participant or Lecturer; Urology Association of Physician Assistants: Leadership Position, Meeting Participant or Lecturer
  • Tricia Zubert, NP: Nothing to disclose

Method of Participation
Learners will participate in this online educational activity by taking an online pre- and post-test and viewing the online video. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.

Estimated time to complete this activity: 4.5 hours
 
Release Date: June, 2017
Expiration Date: June, 2018
 
Accreditation Statement
 
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
 
Credit Designation
 
The American Urological Association designates this enduring material for a maximum of 4.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
If you have already received credit for this course by attending it or watching it live you cannot receive additional credit.

AAFP Accreditation: This Enduring Material activity, Urology Update 2017: For Primary Care and Advanced Practice Providers Webcast, has been reviewed and is acceptable for up to 4.50 Prescribed credit(s) by the American Academy of Family Physicians. AAFP certification begins 06/01/2017. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Other Learners
 
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
 
Evidence Based Content
 
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
 
AUA Disclosure Policy 
 
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) participating in an educational activity provided by the AUA are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
 
Resolution of Identified Conflict of Interest
 
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
 

  • Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
  • Limit content to evidence with no recommendations
  • Introduction of a debate format with an unbiased moderator (point-counterpoint)
  • Inclusion of moderated panel discussion
  • Publication of a parallel or rebuttal article for an article that is felt to be biased
  • Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
  • Divestiture of the relationship by faculty

 
Off-label or Unapproved Use of Drugs or Devices
 
It is the policy of the AUA to require the disclosure of all references to off-label or unapproved uses of drugs or devices prior to the presentation of educational content. The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
 
Disclaimer
 
The opinions and recommendations expressed by faculty, authors and other experts whose input is included in this program are their own and do not necessarily represent the viewpoint of the AUA.

Acknowledgements
The AUA Office of Education would like to thank the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support:

  • Allergan
  • Astellas
  • Pfizer

AUAER ensures that all educational activities are developed and implemented independent of the control and/or influence of any commercial interests (ACCME: SCS1)

 
Reproduction Permission
 
Reproduction of written materials developed for this AUA course is prohibited without the written permission from individual authors and the American Urological Association.
  
AUA Privacy and Confidentiality Policy
www.auanet.org/education/confidentiality-statement.cfm
 
Contact Information 
American Urological Association
Office of Education
1000 Corporate Blvd.
Linthicum, MD 21090
Toll Free (U.S. only): 1-866-RING AUA (1-866-746-4282)
Phone: 410-689-3700
Fax: 410-689-3800
 
CME Information
For all inquiries regarding CME credit email: education@AUAnet.org

Available Credit

  • 4.50 AMA PRA Category 1 Credit™
  • 4.50 Non-Physician Participation
  • 4.50 AAFP Prescribed

Accreditation Period

Course opens: 
06/01/2017
Course expires: 
06/01/2018
Please login or register to take this course.